Suppr超能文献

Toll样受体在肌营养不良蛋白缺乏的骨骼肌和心肌发病机制中的作用。

Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.

作者信息

Henriques-Pons Andrea, Yu Qing, Rayavarapu Sree, Cohen Tatiana V, Ampong Beryl, Cha Hee Jae, Jahnke Vanessa, Van der Meulen Jack, Wang Daqing, Jiang Weiwen, Kandimalla Ekambar R, Agrawal Sudhir, Spurney Chistopher F, Nagaraju Kanneboyina

机构信息

Center for Genetic Medicine Research.

出版信息

Hum Mol Genet. 2014 May 15;23(10):2604-17. doi: 10.1093/hmg/ddt656. Epub 2013 Dec 23.

Abstract

Although the cause of Duchenne muscular dystrophy (DMD) is known, the specific factors that initiate and perpetuate disease progression are not well understood. We hypothesized that leaky dystrophin-deficient skeletal muscle releases endogenous danger signals (TLR ligands), which bind to Toll-like receptors (TLRs) on muscle and immune cells and activate downstream processes that facilitate degeneration and regeneration in dystrophic skeletal muscle. Here, we demonstrate that dystrophin-deficient mouse muscle cells show increased expression of several cell-surface and endosomal TLRs. In vitro screening identified ssRNA as a relevant endogenous TLR7 ligand. TLR7 activation led to myd88-dependent production of pro-inflammatory cytokines in dystrophin-deficient muscle cells, and cause significant degeneration/regeneration in vivo in mdx mouse muscle. Also, knockout of the central TLR adaptor protein, myd88 in mdx mice significantly improved skeletal and cardiac muscle function. Likewise, proof-of-concept experiments showed that treating young mdx mice with a TLR7/9 antagonist significantly reduced skeletal muscle inflammation and increased muscle force, suggesting that blocking this pathway may have therapeutic potential for DMD.

摘要

尽管杜氏肌营养不良症(DMD)的病因已知,但启动并维持疾病进展的具体因素仍未完全明确。我们推测,缺乏抗肌萎缩蛋白的骨骼肌渗漏会释放内源性危险信号(TLR配体),这些信号与肌肉和免疫细胞上的Toll样受体(TLR)结合,并激活下游过程,促进营养不良性骨骼肌的退化和再生。在此,我们证明缺乏抗肌萎缩蛋白的小鼠肌肉细胞中几种细胞表面和内体TLR的表达增加。体外筛选确定单链RNA为相关的内源性TLR7配体。TLR7激活导致抗肌萎缩蛋白缺陷型肌肉细胞中依赖髓样分化因子88(myd88)产生促炎细胞因子,并在mdx小鼠肌肉中引起显著的退化/再生。此外,在mdx小鼠中敲除核心TLR衔接蛋白myd88可显著改善骨骼肌和心肌功能。同样,概念验证实验表明,用TLR7/9拮抗剂治疗年轻的mdx小鼠可显著减轻骨骼肌炎症并增加肌肉力量,这表明阻断该途径可能对DMD具有治疗潜力。

相似文献

1
Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.
Hum Mol Genet. 2014 May 15;23(10):2604-17. doi: 10.1093/hmg/ddt656. Epub 2013 Dec 23.
2
Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Exp Physiol. 2014 Apr;99(4):675-87. doi: 10.1113/expphysiol.2013.077255. Epub 2014 Jan 17.
3
MyD88 is required for satellite cell-mediated myofiber regeneration in dystrophin-deficient mdx mice.
Hum Mol Genet. 2018 Oct 1;27(19):3449-3463. doi: 10.1093/hmg/ddy258.
4
miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Skelet Muscle. 2019 Aug 14;9(1):22. doi: 10.1186/s13395-019-0207-0.
8
Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice.
J Mol Histol. 2004 Jun;35(5):489-99. doi: 10.1023/b:hijo.0000045947.83628.a7.
10
Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice.
PLoS One. 2013 Aug 15;8(8):e72121. doi: 10.1371/journal.pone.0072121. eCollection 2013.

引用本文的文献

1
Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis.
Front Immunol. 2025 Mar 3;16:1527840. doi: 10.3389/fimmu.2025.1527840. eCollection 2025.
3
Hypoxia-induced PD-L1 expression and modulation of muscle stem cell allograft rejection.
Front Pharmacol. 2024 Nov 1;15:1471563. doi: 10.3389/fphar.2024.1471563. eCollection 2024.
4
Nanomaterial-Mediated Reprogramming of Macrophages to Inhibit Refractory Muscle Fibrosis.
Adv Mater. 2024 Dec;36(52):e2410368. doi: 10.1002/adma.202410368. Epub 2024 Nov 16.
6
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.
Front Physiol. 2023 Jun 26;14:1183101. doi: 10.3389/fphys.2023.1183101. eCollection 2023.
7
Trained immunity as a potential target for therapeutic immunomodulation in Duchenne muscular dystrophy.
Front Immunol. 2023 Jun 15;14:1183066. doi: 10.3389/fimmu.2023.1183066. eCollection 2023.
8
Nanomedicine for Treating Muscle Dystrophies: Opportunities, Challenges, and Future Perspectives.
Int J Mol Sci. 2022 Oct 10;23(19):12039. doi: 10.3390/ijms231912039.
9
TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy.
Nat Commun. 2022 Feb 15;13(1):879. doi: 10.1038/s41467-022-28531-1.

本文引用的文献

3
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
Nucleic Acids Res. 2013 Apr 1;41(6):3947-61. doi: 10.1093/nar/gkt078. Epub 2013 Feb 8.
4
Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse.
Mol Cell Proteomics. 2013 May;12(5):1061-73. doi: 10.1074/mcp.M112.023127. Epub 2013 Jan 7.
5
Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model.
Skelet Muscle. 2012 Aug 21;2(1):16. doi: 10.1186/2044-5040-2-16.
6
The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.
Arthritis Rheum. 2012 Nov;64(11):3750-9. doi: 10.1002/art.34625.
7
Innate immune signaling in cardiac ischemia.
Nat Rev Cardiol. 2011 May;8(5):292-300. doi: 10.1038/nrcardio.2011.38. Epub 2011 Mar 29.
9
Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle.
Am J Pathol. 2010 Jun;176(6):2891-900. doi: 10.2353/ajpath.2010.090058. Epub 2010 Apr 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验